Physician profile
Eugene Ng
NPI 1609021831
$10,281.21
in general payments reported to CMS, 2019-2025
28 companies · $3,453 in 2025
The $3,453 reported for 2025 was more than what 86% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $365 · 2021: $455 · 2022: $1,310 · 2023: $1,055 · 2024: $3,338 · 2025: $3,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,561 · Travel and Lodging: $1,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,561.30 |
| Travel and Lodging | $1,283.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,325.81 | 2019-2025 | Argos, Clareon, Clareon Panoptix Pro |
| Abbvie INC. | $1,745.76 | 2022-2025 | |
| Genentech USA, INC. | $1,425.32 | 2022-2025 | Vabysmo, Susvimo |
| Sight Sciences, INC. | $537.90 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Intuitive Surgical, INC. | $406.94 | 2024 | |
| Glaukos Corporation | $352.17 | 2024-2025 | Idose, Idosetr |
| Oyster Point Pharma, INC. | $287.29 | 2023 | Tyrvaya |
| Regeneron Healthcare Solutions, INC. | $232.66 | 2020-2024 | Eylea Hd |
| Sun Pharmaceutical Industries INC. | $213.07 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $190.72 | 2024-2025 | Purified Cortrophin Gel, Iluvien |
| Dompe US, INC. | $188.73 | 2025 | Oxervate |
| Alimera Sciences, INC. | $175.36 | 2020 | |
| Lkc Technologies, INC. | $142.78 | 2025 | |
| Novartis Pharmaceuticals Corporation | $136.61 | 2019-2022 | |
| Allergan, INC. | $134.04 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heidelberg Engineering, INC. | $127.79 | 2025 | Spectralis |
| Eyepoint US, INC. | $108.42 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $105.61 | 2021-2025 | Acthar |
| Regeneron Pharmaceuticals, INC. | $103.93 | 2024 | Eylea, Eylea Hd |
| Johnson & Johnson Surgical Vision, INC. | $76.57 | 2019 | |
| Lumibird Medical INC. | $64.65 | 2025 | |
| Dutch Ophthalmic, USA | $37.96 | 2023 | Eva, Combined Machine, Tissueblue |
| Amgen INC. | $36.24 | 2025 | Tepezza |
| Apellis Pharmaceuticals, INC. | $33.60 | 2025 | Syfovre |
| Synergeyes, INC. | $32.93 | 2019 | |
| Coherus Oncology, INC. | $20.83 | 2023 | |
| Mallinckrodt Enterprises LLC | $19.52 | 2019 | |
| Kala Pharmaceuticals, INC. | $18.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Ng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.